Journal: Nature Medicine

Article Title: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

doi: 10.1038/s41591-026-04449-9

Figure Lengend Snippet: Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.

Article Snippet: Antibodies for the TCR/DC panel included TCRγδ Vio Blue (Miltenyi Biotec, cat. no.1 30-119-619), TCRαβ FITC (Miltenyi Biotec, cat. no. 130-113-538), CD83 PE (Miltenyi Biotec, cat. no. 130-110-503), CD3 Per CP Vio-770 (Miltenyi Biotec, cat. no. 130-113-141) and CD45 APC (Miltenyi Biotec, cat. no. 130-110-633).

Techniques: Enzyme-linked Immunospot, Whisker Assay

Journal: Nature Medicine

Article Title: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

doi: 10.1038/s41591-026-04449-9

Figure Lengend Snippet: a-f ) Longitudinal tracking of product‑derived clonotypes for assayed participants who received infusion of specific TAA‑T products. Time points corresponding to disease progression (if applicable) are indicated by the downward black arrow. Abbreviations : “Pre” = prior to first TAA‑T cell infusion; I = infusion; W = week; M = month. ( a ) P09 (Arm B). b ) P12 (Arm B). c ) P10 (Arm A). d ) P20 (Arm B). e ) P26 (Arm B). f ) P35 (Arm B). g ) Global TCR Repertoire Dynamics (Arms B/C) – Simpson Clonality. Color coding indicates participants with increases in Simpson’s Clonality relative to baseline. Baseline PBMC samples are from the pre-infusion time point for Arm B. For Arm C patients, post lymphodepletion, pre-infusion samples were not available for all patients so week 1 post-infusion was first available time point sampled longitudinally.

Article Snippet: Antibodies for the TCR/DC panel included TCRγδ Vio Blue (Miltenyi Biotec, cat. no.1 30-119-619), TCRαβ FITC (Miltenyi Biotec, cat. no. 130-113-538), CD83 PE (Miltenyi Biotec, cat. no. 130-110-503), CD3 Per CP Vio-770 (Miltenyi Biotec, cat. no. 130-113-141) and CD45 APC (Miltenyi Biotec, cat. no. 130-110-633).

Techniques: Biomarker Discovery

Journal: Cancer Medicine

Article Title: STEAP1 Suppresses Oral Squamous Cell Carcinoma by Targeting Wnt/β‐Catenin Signalling and EMT

doi: 10.1002/cam4.71862

Figure Lengend Snippet: STEAP1 Effect on the wnt/β‐catenin signalling pathway in OSCC cell lines. (A–J) The effect of STEAP1 on the wnt/β‐catenin signalling pathway in SAS and Tca‐8113 cells was assessed and quantitatively analysed by Western Blot. (* p < 0.05, ** p < 0.01, **** p < 0.0001).

Article Snippet: China); a mouse anti‐human β‐actin antibody (TA‐09, ZSBIO, China); a rabbit anti‐human P‐GSK‐3β antibody (BM4837, BOSTER, China); a rabbit anti‐human GSK‐3β antibody (A00791‐3, BOSTER, China); a rabbit anti‐human β‐catenin antibody (PA1212, BOSTER, China); primary rabbit anti‐human c‐Myc antibody ( T55150 , Abmart, China); primary rabbit anti‐human Axin2 antibody ( R23574 , ZENBIO, China); secondary goat anti‐mouse IgG antibody (ZB2305, ZSBIO, China); secondary goat anti‐rabbit IgG antibody (ZB2301, ZSBIO, China).

Techniques: Western Blot